Magnesium Supplementation With Fluoxetine for Cognitive Function in Depression

Summary

The goal of this clinical trial is to evaluate whether magnesium supplementation can improve cognitive function in patients with depression receiving fluoxetine therapy. It also aims to assess its effect on serum brain-derived neurotrophic factor (BDNF) levels in adult patients with depression. The main questions it aims to answer are: * Does magnesium supplementation improve cognitive function in patients with depression receiving fluoxetine? * Does magnesium supplementation increase serum BDNF levels in these patients? Researchers will compare patients receiving fluoxetine with magnesium supplementation to those receiving fluoxetine alone to determine whether magnesium provides additional benefits. Participants will: * Receive fluoxetine therapy with or without magnesium supplementation for 6 weeks * Undergo cognitive assessment using the Montreal Cognitive Assessment (MoCA) at baseline and after treatment * Provide blood samples for measurement of serum BDNF levels at baseline and after 6 weeks

Timeline

Start

2025-07-01

Primary completion

2025-08-01

Completion

2025-08-01

Drugs

Indications